2023 CPT Code Updates (CDM Focused)

2023 CPT® Code
Updates (CDM Focused)

Jennifer Bishop
RHIT, CCS, CCS-P, CHRI

Overview of 2023 Changes
CPT® Section Additions Deletions Revisions
Evaluation &
Management
1 26 50
Anesthesia 0 0 0
Surgery 33 19 22
Radiology 1 0 5
Pathology & Laboratory 11 0 3
PLA 9 0 0
Medicine 10 0 7
Category II 0 0 0
Category III 46 22 2
Totals 111 67 89
• Totals do not include codes added, deleted, or revised in CY 2021/2022 but appearing for the first time in the CY 2023 book
• Revised totals do not include codes with changes to short or medium descriptions only

Added Code - Radiology Section
 76883 - Ultrasound, nerve(s) and accompanying structures throughout their
entire anatomic course in one extremity, comprehensive, including real-time
cine imaging with image documentation, per extremity
 Requires evaluation of the entire course of a nerve in the extremity
 Cannot be reported with 76882 for the same nerve
 Comprehensive evaluation requires acquisition and permanent record of cine
clips and static images to demonstrate the anatomy

Revised Codes - Radiology Section
Code 2023 Long Description 2022 Long Description
76882 Ultrasound, limited, joint or focal evaluation of
other nonvascular extremity structure(s) (eg, joint
space, peri-articular tendon[s], muscle[s], nerve[s],
other soft-tissue structure[s], or soft-tissue
mass[es]), real-time with image documentation
Ultrasound, limited, joint or other nonvascular
extremity structure(s) (eg, joint space, peri-
articular tendon[s], muscle[s], nerve[s], other soft-
tissue structure[s], or soft-tissue mass[es]), real-
time with image documentation
 76882 represents a limited evaluation of a joint or focal evaluation of a structure(s) in the extremity
other than a joint; evaluation will not include all of the required elements outlined in code 76881
 Must have permanent records of imaging

78803 Radiopharmaceutical localization of tumor,
inflammatory process or distribution of
radiopharmaceutical agent(s) (includes vascular flow
and blood pool imaging, when performed);
tomographic (SPECT), single area (eg, head, neck,
chest, pelvis), or acquisition, single day imaging
Radiopharmaceutical localization of tumor,
tomographic (SPECT), single area (eg, head, neck,
chest, pelvis), single day imaging
78830 Radiopharmaceutical localization of tumor,
tomographic (SPECT) with concurrently acquired
computed tomography (CT) transmission scan for
anatomical review, localization and
determination/detection of pathology, single area (eg,
head, neck, chest, pelvis), or acquisition, single day
imaging
Radiopharmaceutical localization of tumor,
tomographic (SPECT) with concurrently acquired
computed tomography (CT) transmission scan for
anatomical review, localization and
determination/detection of pathology, single area (eg,
head, neck, chest, pelvis), single day imaging

78831 Radiopharmaceutical localization of tumor, inflammatory process
or distribution of radiopharmaceutical agent(s) (includes vascular
flow and blood pool imaging, when performed); tomographic
(SPECT), minimum 2 areas (eg, pelvis and knees, chest and
abdomen) or separate acquisitions (eg, lung ventilation and
perfusion), single day imaging, or single area or acquisition over
2 or more days
Radiopharmaceutical localization of tumor, inflammatory
process or distribution of radiopharmaceutical agent(s)
(includes vascular flow and blood pool imaging, when
performed); tomographic (SPECT), minimum 2 areas (eg,
pelvis and knees, abdomen and pelvis), single day imaging,
or single area imaging over 2 or more days
78832 Radiopharmaceutical localization of tumor, inflammatory process
or distribution of radiopharmaceutical agent(s) (includes vascular
flow and blood pool imaging, when performed); tomographic
(SPECT) with concurrently acquired computed tomography (CT)
transmission scan for anatomical review, localization and
determination/detection of pathology, minimum 2 areas (eg,
pelvis and knees, chest and abdomen) or separate acquisitions
(eg, lung ventilation and perfusion), single day imaging, or single
area or acquisition over 2 or more days
Radiopharmaceutical localization of tumor, inflammatory
process or distribution of radiopharmaceutical agent(s)
(includes vascular flow and blood pool imaging, when
performed); tomographic (SPECT) with concurrently
acquired computed tomography (CT) transmission scan for
anatomical review, localization and determination/detection
of pathology, minimum 2 areas (eg, pelvis and knees,
abdomen and pelvis), single day imaging, or single area
imaging over 2 or more days
 Codes revised to clarify differentiation between single area/acquisition exams versus 2+ acquisitions
with 2 different radiopharmaceuticals

Changes to
Laboratory &
Pathology Section

Updated Definitions/Guidelines –
Genomic Sequencing Procedures (GSPs)
 GSPs (81410-81471) are DNA or RNA sequence analysis methods that simultaneously
assay multiple genes or genetic regions relevant to a clinical situation.
 They typically use next generation sequencing (NGS) or massively parallel sequencing
(MPS), but other technology may be used
 May target specific combinations of genes or genetic material or assay the exome or
genome
 The exome and genome procedures are designed to evaluate the genetic material in
totality or near totality
 Codes are used when the components of the descriptor are performed regardless of
technique used
 When a GSP assay includes genes listed in more than one code descriptor, select the
code for the primary disorder sought
 When all components of the descriptor are not performed, use Tier 1-2 codes or 81479

Added Codes – Genomic Sequencing
Procedures (GSPs)
 81418 – Drug metabolism (eg, pharmacogenomics) genomic sequence
analysis panel, must include testing of at least 6 genes, including CYP2C19,
CYP2D6, and CYP2D6 duplication/deletion analysis
 81441 - Inherited bone marrow failure syndromes (IBMFS) (eg, Fanconi
anemia, dyskeratosis congenita, Diamond-Blackfan anemia, Shwachman-
Diamond syndrome, GATA2 deficiency syndrome, congenital
amegakaryocytic thrombocytopenia) sequence analysis panel, must include
sequencing of at least 30 genes, including BRCA2, BRIP1, DKC1, FANCA,
FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL,
GATA1, GATA2, MPL, NHP2, NOP10, PALB2, RAD51C, RPL11, RPL35A,
RPL5, RPS10, RPS19, RPS24, RPS26, RPS7, SBDS, TERT, and TINF2

Procedures (GSPs)
 81449 – Targeted genomic sequence analysis panel, solid organ neoplasm,
5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, MET,
NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for
sequence variants and copy number variants or rearrangements, if
performed; RNA analysis
 81451 - Targeted genomic sequence analysis panel, hematolymphoid
neoplasm or disorder, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2,
FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NOTCH1, NPM1, NRAS),
interrogation for sequence variants, and copy number variants or
rearrangements, or isoform expression or mRNA expression levels, if
performed; RNA analysis

Procedures
 81456 - Targeted genomic sequence analysis panel, solid organ or
hematolymphoid neoplasm or disorder, 51 or greater genes (eg, ALK, BRAF,
CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2,
JAK2, KIT, KRAS, MET, MLL, NOTCH1, NPM1, NRAS, PDGFRA, PDGFRB,
PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy
number variants or rearrangements, or isoform expression or mRNA
expression levels, if performed; RNA analysis

Revised Codes - GSP
81445 Targeted genomic sequence analysis panel, solid organ neoplasm, 5-50
genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, MET,
NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation
for sequence variants and copy number variants or rearrangements, if
performed; DNA analysis or combined DNA and RNA analysis
Targeted genomic sequence analysis panel, solid organ neoplasm,
DNA analysis, and RNA analysis when performed, 5-50 genes (eg,
ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET,
PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for
sequence variants and copy number variants or rearrangements, if
performed
81450 Targeted genomic sequence analysis panel, hematolymphoid neoplasm
or disorder, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2, FLT3,
IDH1, IDH2, JAK2, KIT, KRAS, MLL, NOTCH1, NPM1, NRAS),
performed; DNA analysis or combined DNA and RNA analysis
Targeted genomic sequence analysis panel, hematolymphoid
neoplasm or disorder, DNA analysis, and RNA analysis when
performed, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2, FLT3,
IDH1, IDH2, JAK2, KRAS, KIT, MLL, NRAS, NPM1, NOTCH1),
performed
81455 Targeted genomic sequence analysis panel, solid organ or
hematolymphoid neoplasm or disorder, 51 or greater genes (eg, ALK,
BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1,
IDH2, JAK2, KIT, KRAS, MET, MLL, NOTCH1, NPM1, NRAS, PDGFRA,
PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence
variants and copy number variants or rearrangements, or isoform
expression or mRNA expression levels, if performed; DNA analysis or
combined DNA and RNA analysis
Targeted genomic sequence analysis panel, solid organ or
hematolymphoid neoplasm, DNA analysis, and RNA analysis when
performed, 51 or greater genes (eg, ALK, BRAF, CDKN2A, CEBPA,
DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT,
KRAS, MLL, NPM1, NRAS, MET, NOTCH1, PDGFRA, PDGFRB,
PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and
copy number variants or rearrangements, if performed

Updated Definitions/Guidelines –
Genomic Sequencing Procedures (GSP)
 Testing for somatic alterations in neoplasms may be reported differently based
on whether combined methods and analyses are used for both DNA and RNA
analytes, or if separate methods and analyses are used for each analyte
 For targeted genomic sequence DNA analysis or for DNA and RNA analysis
using a single combined method, report 81445, 81450, or 81455
 For targeted genomic sequence RNA analysis using a separate method, report
81449, 81451, or 81456
 For targeted genomic sequence DNA analysis and RNA analysis performed
separately, report 81445, 81450, or 81455 for the DNA analysis AND 81449,
81451, or 81456 for the RNA analysis

Added Code – Chemistry
 84433 – Thiopurine S-methyltransferase (TPMT)
 Used to detect a thiopurine methyltransferase (TPMT) deficiency and to
determine the risk of developing severe side effects if treated with the class
of immune-suppressing thiopurine drugs that includes azathioprine,
mercaptopurine, and thioguanine

Added Codes – Microbiology
 87467 - Hepatitis B surface antigen (HBsAg), quantitative
 Primarily used to monitor drug therapy; for qualitative analysis, see 87340
 87468 - Infectious agent detection by nucleic acid (DNA or RNA); Anaplasma
phagocytophilum, amplified probe technique
 87469 - Infectious agent detection by nucleic acid (DNA or RNA); Babesia
microti, amplified probe technique
 87478 - Infectious agent detection by nucleic acid (DNA or RNA); Borrelia
miyamotoi, amplified probe technique
 87484 - Infectious agent detection by nucleic acid (DNA or RNA); Ehrlichia
chaffeensis, amplified probe technique
 New codes will allow for greater specificity in tracking of tick-borne illnesses

Changes to
Proprietary
Laboratory
Analyses (PLA)
Codes

Added Codes – PLA
 0355U - APOL1 (apolipoprotein L1) (eg, chronic kidney disease), risk variants
(G1, G2)
 Apolipoprotein L1 (APOL1) Renal Risk Variant Genotyping from Quest Diagnostics®
 Used to assist in evaluation of a potential kidney transplant donor
 0356U - Oncology (oropharyngeal), evaluation of 17 DNA biomarkers using
droplet digital PCR (ddPCR), cell-free DNA, algorithm reported as a
prognostic risk score for cancer recurrence
 NavDx® from Naveris, Inc.
 Circulating DNA blood test that aids in the detection of HPV-driven cancer

Added Codes – PLA
 0357U - Oncology (melanoma), artificial intelligence (AI)-enabled quantitative
mass spectrometry analysis of 142 unique pairs of glycopeptide and product
fragments, plasma, prognostic, and predictive algorithm reported as likely,
unlikely, or uncertain benefit from immunotherapy agents
 DAWN™ IO Melanoma from InterVenn Biosciences
 Measures glycoproteins using AI technology to match cancer patients with best therapy
 0358U - Neurology (mild cognitive impairment), analysis of β-amyloid 1-42
and 1-40, chemiluminescence enzyme immunoassay, cerebral spinal fluid,
reported as positive, likely positive, or negative
 Lumipulse® G β-Amyoid Ratio (1-42/1-40) Test by Fujirebio Diagnostics, Inc
 Measures β-Amyloid to detect formation of amyloid plaques early in Alzheimer’s disease

Added Codes – PLA
 0359U - Oncology (prostate cancer), analysis of all prostate-specific antigen
(PSA) structural isoforms by phase separation and immunoassay, plasma,
algorithm reports risk of cancer
 IsoPSA® from Cleveland Diagnostics, Inc
 PSA assay for patients with a PSA > 4ng/mL to help with decision for biopsy procedure
 0360U - Oncology (lung), enzyme-linked immunosorbent assay (ELISA) of 7
autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, and
HuD), plasma, algorithm reported as a categorical result for risk of
malignancy
 Nodify CDT® from Biodesix, Inc
 Blood test to assess risk of lung cancer in patients with lung nodule(s)

Added Codes – PLA
 0361U - Neurofilament light chain, digital immunoassay, plasma, quantitative
 Neurofilament Light Chain (NfL) from Mayo Clinic
 Blood biomarker test used to determine if cognitive issues may be related to a
neurodegenerative condition
 0362U - Oncology (papillary thyroid cancer), gene-expression profiling via
targeted hybrid capture–enrichment RNA sequencing of 82 content genes
and 10 housekeeping genes, formalin-fixed paraffin embedded (FFPE)
tissue, algorithm reported as one of three molecular subtypes
 Thyroid GuidePx® from Protean BioDiagnostics
 NGS RNA sequencing of 82 genes to determine molecular subtype of papillary thyroid
cancer

Added Codes – PLA
 0363U - Oncology (urothelial), mRNA, gene-expression profiling by real-time
quantitative PCR of 5 genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and
CXCR2), utilizing urine, algorithm incorporates age, sex, smoking history, and
macrohematuria frequency, reported as a risk score for having urothelial
carcinoma
 Cxbladder™ Triage from Pacific Edge Diagnostics USA, Ltd
 Measures gene expression levels of five biomarkers using urine to determine risk of
bladder cancer

Added Code – Vaccines/Toxoids
 90678 - Respiratory syncytial virus vaccine, preF, subunit, bivalent, for
intramuscular use
 RSVpreF vaccine (will be active when approved by the FDA)
 Indicated for patients 60 years and older and for patients in their 2nd or 3rd trimester of
pregnancy

Added Codes – Ophthalmology Services
 92066 - Orthoptic training; under supervision of a physician or other qualified
health care professional
 Change made to differentiate whether physician or technician are performing the
procedure

Revised Code – Ophthalmology Services
92065 Orthoptic training; performed by a physician or other
qualified health care professional
Orthoptic training
92229 Imaging of retina for detection or monitoring of disease;
point-of-care autonomous analysis and report, unilateral
or bilateral
Imaging of retina for detection or monitoring of
disease; point-of-care automated analysis and
report, unilateral or bilateral
92284 Diagnostic dark adaptation examination with
interpretation and report
Dark adaptation examination with interpretation and
report

Added Codes – Nerve Conduction Tests
 95919 - Quantitative pupillometry with physician or other qualified health care
professional interpretation and report, unilateral or bilateral
 Used in both immediate evaluation and ongoing management of traumatic brain injuries
 Provides objective data as opposed to subjective data

Added Codes – Behavior Management
Services
 96202 - Multiple-family group behavior management/modification training for
parent(s)/guardian(s)/caregiver(s) of patients with a mental or physical health
diagnosis, administered by physician or other qualified health care professional
(without the patient present), face-to-face with multiple sets of
parent(s)/guardian(s)/caregiver(s); initial 60 minutes
 96203 - Multiple-family group behavior management/modification training for
parent(s)/guardian(s)/caregiver(s) of patients with a mental or physical health
diagnosis, administered by physician or other qualified health care professional
(without the patient present), face-to-face with multiple sets of
parent(s)/guardian(s)/caregiver(s); each additional 15 minutes (List separately in
addition to code for primary service)
 Used to report face-to-face time spent providing group-based behavioral management or
modification training to parents, guardians, or caregivers
 Behavior modification is the process of altering behavior patterns over a long-term period
using motivational techniques to replace unwanted behaviors with more positive behaviors

Added Codes – Cardiovascular
 93569 - Injection procedure during cardiac catheterization including imaging
supervision, interpretation, and report; for selective pulmonary arterial angiography,
unilateral (List separately in addition to code for primary procedure)
supervision, interpretation, and report; for selective pulmonary arterial angiography,
bilateral (List separately in addition to code for primary procedure)
supervision, interpretation, and report; for selective pulmonary venous angiography of
each distinct pulmonary vein during cardiac catheterization (List separately in
addition to code for primary procedure)
supervision, interpretation, and report; for selective pulmonary angiography of major
aortopulmonary collateral arteries (MAPCAs) arising off the aorta or its systemic
branches, during cardiac catheterization for congenital heart defects, each distinct
vessel (List separately in addition to code for primary procedure)

Added Codes - Cardiovascular
 Three new codes have been added to differentiate between angiography
of the pulmonary arteries (unilateral versus bilateral) and pulmonary
veins during cardiac catheterization (93569, 93573, 93574)
 One new code has been added to capture angiography of major
aortopulmonary collateral arteries during cardiac catheterization (93575)
 All codes include selective introduction and positioning of catheter, injection,
and all radiologic S&I
 A distinct vessel must be selectively cannulated in order to report each
instance of 93574 or 93575
 Superior or inferior pulmonary veins (93574) or named major aortopulmonary
collateral artery (MAPCA) (93575)

Image published in RSNA Journal, Vol.4, No.1, published online Feb 3, 2022, at
https://doi.org/10.1148/ryct.210157

Revised Code – Medicine/Cardiovascular
93568 Injection procedure during cardiac
catheterization including imaging supervision,
interpretation, and report; for nonselective
pulmonary arterial angiography (List separately
in addition to code for primary procedure)
Injection procedure during cardiac
catheterization including imaging supervision,
interpretation, and report; for pulmonary
angiography (List separately in addition to code
for primary procedure)
 93568 has been revised to report non-selective pulmonary arterial angiography

Updated Definitions & Guidelines –
Coronary Therapeutic Services
 Percutaneous coronary intervention codes 92920-92944 are built on hierarchies
with more intensive services inclusive of lesser intensive services
 All codes include angioplasty, when performed
 Codes all include accessing and selectively catheterizing the vessel, crossing
the lesion, radiological S&I related to the procedure, closing the arteriotomy, and
performing imaging to verify outcome of the procedure
 Diagnostic coronary angiography may be separately reported IF A) There is no prior
study available, and a full diagnostic study is performed; or B) A prior study is
available, but there is documentation that the prior study is inadequate, there has
been a clinical change in the patient since the prior study; or C) There is a clinical
change during the procedure that warrants a separate study
 Percutaneous transluminal coronary lithotripsy may be separately reported using
0715T

Cardiac Catheterization
 New guidance given on appropriate codes to use during cardiac catheterization
for congenital versus non-congenital heart disease
 Left ventriculography is included in LHC for non-congenital heart disease, but is
separately reported when performed for congenital heart defects using 93565
 Supravalvular aortography is separately reported using 93567
 Pulmonary angiography and selective venous angiography are separately
reported using appropriate code(s)
 Code 93463 is reported when drugs are given for the specific purpose of
evaluating hemodynamic response through repeat hemodynamic measurements
 93463 is not reported for administration of drugs during percutaneous coronary
intervention; during assessment of coronary pressure, flow, or resistance; or during
imaging procedures

Remote Therapeutic Monitoring
 Used to report review and monitoring of data related to signs, symptoms, and
functions of a therapeutic response. Data may represent objective device-
generated data or subjective data from patient
 Codes 98976-98978 are used to report services during a 30-day period; do not
report for monitoring of less than 16 days
 Service must be ordered by a physician or other QHP, device must be a medical
device as defined by the FDA
 Do not report with other physiologic monitoring services like glucose monitoring
or remote monitoring of physiologic parameters
 98975 is reported once for each episode of care, defined as the beginning of
monitoring through the attainment of targeted treatment goal(s)

Added Code – Remote Therapeutic
Monitoring
One New Code Created to Report Remote Therapeutic Monitoring
Services
 98978 – Remote therapeutic monitoring (eg, therapy adherence, therapy
response); device(s) supply with scheduled (eg, daily) recording(s) and/or
programmed alert(s) transmission to monitor cognitive behavioral therapy,
each 30 days

Revised Codes – Remote Therapeutic
Monitoring
98975 Remote therapeutic monitoring (eg, therapy adherence,
therapy response); initial set-up and patient education on
use of equipment
Remote therapeutic monitoring (eg, respiratory system
status, musculoskeletal system status, therapy
adherence, therapy response); initial set-up and patient
education on use of equipment
therapy response); device(s) supply with scheduled (eg,
daily) recording(s) and/or programmed alert(s)
transmission to monitor respiratory system, each 30 days
adherence, therapy response); device(s) supply with
scheduled (eg, daily) recording(s) and/or programmed
alert(s) transmission to monitor respiratory system, each
30 days
therapy response); device(s) supply with scheduled (eg,
daily) recording(s) and/or programmed alert(s)
transmission to monitor musculoskeletal system, each 30
days
adherence, therapy response); device(s) supply with
scheduled (eg, daily) recording(s) and/or programmed
alert(s) transmission to monitor musculoskeletal system,
each 30 days

Added Codes - New & Emerging
Technology
Code Long Description
0738T Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from
previously performed magnetic resonance imaging (MRI) examination
0742T Absolute quantitation of myocardial blood flow (AQMBF), single-photon emission computed
tomography (SPECT), with exercise or pharmacologic stress, and at rest, when performed (List
separately in addition to code for primary procedure)
 0738T may not be reported with 0739T (tissue ablation)
 AQMBF done with PET imaging is reported using 78434

Added Codes - New & Emerging
Technology
0740T Remote autonomous algorithm-based recommendation system for insulin dose calculation and
titration; initial set-up and patient education
0741T Remote autonomous algorithm-based recommendation system for insulin dose calculation and
titration; provision of software, data collection, transmission, and storage, each 30 days
 New technology to provide patients with real-time information to calculate appropriate adjusted
insulin doses
 Hygieia’s d-Nav® Technology

Added Codes
New & Emerging Technology
0743T Bone strength and fracture risk using finite element analysis of functional data and bone mineral
density (BMD), with concurrent vertebral fracture assessment, utilizing data from a computed
tomography scan, retrieval and transmission of the scan data, measurement of bone strength and
BMD and classification of any vertebral fractures, with overall fracture-risk assessment,
 0743T includes vertebral fracture assessment, which differentiates this code from 0554T-0557T
 0558T may be separately reported when performed with a concurrently obtained CT scan

Added Codes
0749T Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density
(DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and
transmission of digital X-ray data, assessment of bone strength and fracture risk and BMD,
0750T Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density
(DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and
transmission of digital X-ray data, assessment of bone strength and fracture risk and BMD,
interpretation and report; with single-view digital X-ray examination of the hand taken for the purpose
of DXR-BMD
 0749T is reported when an appropriate digital x-ray is available
 0750T is reported when a single digital x-ray of the hand is taken for DXR-BMD analysis; x-ray of
hand is not separately reported

Added Codes
0751T Digitization of glass microscope slides for level II, surgical pathology, gross and microscopic
examination (List separately in addition to code for primary procedure)
0752T Digitization of glass microscope slides for level III, surgical pathology, gross and microscopic
0753T Digitization of glass microscope slides for level IV, surgical pathology, gross and microscopic
0754T Digitization of glass microscope slides for level V, surgical pathology, gross and microscopic
0755T Digitization of glass microscope slides for level VI, surgical pathology, gross and microscopic
 Slides are scanned with images used for digital examination for pathologic diagnosis distinct from direct
visualization through a microscope
 May not be used solely for education purposes, for developing a database for training or validation, or for
presentations

Added Codes
0756T Digitization of glass microscope slides for special stain, including interpretation and report, group I,
for microorganisms (eg, acid fast, methenamine silver) (List separately in addition to code for
primary procedure)
0757T Digitization of glass microscope slides for special stain, including interpretation and report, group II,
for microorganisms (eg, acid fast, methenamine silver) (List separately in addition to code for
primary procedure)
0758T Digitization of glass microscope slides for special stain, including interpretation and report,
histochemical stain on frozen tissue block (List separately in addition to code for primary procedure)
0759T Digitization of glass microscope slides for special stain, including interpretation and report, group III,
for enzyme constituents (List separately in addition to code for primary procedure)

Added Codes
0760T Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per
specimen, initial single antibody stain procedure (List separately in addition to code for primary
procedure)
specimen, each additional single antibody stain procedure (List separately in addition to code for
primary procedure)
specimen, each multiplex antibody stain procedure (List separately in addition to code for primary
procedure)
0763T Digitization of glass microscope slides for morphometric analysis, tumor immunohistochemistry (eg,
Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen,
each single antibody stain procedure, manual (List separately in addition to code for primary
procedure)

Added Codes
0764T Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-
ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to concurrently
performed electrocardiogram (List separately in addition to code for primary procedure)
0765T Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-
ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to previously
performed electrocardiogram
 0764T is an add-on code that may be reported with 93000 or 93010 once for each ECG tracing
performed
 0765T may be reported only once for each previously performed ECG tracing
 Anumana, Inc.

Added Codes
0766T Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral
nerve, initial treatment, with identification and marking of the treatment location, including noninvasive
electroneurographic localization (nerve conduction localization), when performed; first nerve
nerve, initial treatment, with identification and marking of the treatment location, including noninvasive
electroneurographic localization (nerve conduction localization), when performed; each additional nerve
(List separately in addition to code for primary procedure)
nerve, subsequent treatment, including noninvasive electroneurographic localization (nerve conduction
localization), when performed; first nerve
nerve, subsequent treatment, including noninvasive electroneurographic localization (nerve conduction
localization), when performed; each additional nerve (List separately in addition to code for primary
procedure)

Transcutaneous Magnetic Nerve Stimulation
 Codes 0766T-0769T describe transcutaneous magnetic stimulation, which is
performed to treat chronic nerve pain
 The nerve is localized using magnetic stimulation, the skin is marked, and the
appropriate amplitude of stimulation is defined
 Non-invasive nerve conduction may be used as guidance to confirm location and
may not be reported separately
 A separate diagnostic nerve conduction study may be separately reported if
performed to determine need for treatment

Added Codes
0770T Virtual reality technology to assist therapy (List separately in addition to code for primary procedure)
0771T Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified
health care professional performing the diagnostic or therapeutic service that the VR procedural
dissociation supports, requiring the presence of an independent, trained observer to assist in the
monitoring of the patient's level of dissociation or consciousness and physiological status; initial 15
minutes of intraservice time, patient age 5 years or older
0772T Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified
health care professional performing the diagnostic or therapeutic service that the VR procedural
dissociation supports, requiring the presence of an independent, trained observer to assist in the
monitoring of the patient's level of dissociation or consciousness and physiological status; each
additional 15 minutes intraservice time (List separately in addition to code for primary service)
 0770T may be reported once per session during which VR technology is used
 May be reported with 90832-90838, 90847-90853, 92507, 92507, 96158, 96159, 96164-96171,
97110, 97112, 97129, 97150, 97153=97155, 97158, 97530, 97533, 97535, 97537

Added Codes
0773T Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health
care professional other than the physician or other qualified health care professional performing the
diagnostic or therapeutic service that the VR procedural dissociation supports; initial 15 minutes of
intraservice time, patient age 5 years or older
0774T Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health
care professional other than the physician or other qualified health care professional performing the
diagnostic or therapeutic service that the VR procedural dissociation supports; each additional 15
minutes intraservice time (List separately in addition to code for primary service)
 VR procedural dissociation is a VR-based state of altered consciousness to decrease pain during a
procedure and increase procedural tolerance by establishing a computer-generated immersive
environment
 0771T-0774T are not used to report administration of medications, moderate sedation, deep
sedation, or MAC

Added Codes
0776T Therapeutic induction of intra-brain hypothermia, including placement of a mechanical temperature-
controlled cooling device to the neck over carotids and head, including monitoring (eg, vital signs
and sport concussion assessment tool 5 [SCAT5]), 30 minutes of treatment
0778T Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU)
sensors for measurement of multi-joint range of motion, posture, gait, and muscle function
0779T Gastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report
0783T Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of
equipment

Deleted Codes
Deleted Code Suggested Replacement Codes
0470T – Optical coherence tomography (OCT) for microstructural and
morphological imaging of skin, image acquisition, interpretation, and
report; first lesion
96999
0471T - Optical coherence tomography (OCT) for microstructural and
morphological imaging of skin, image acquisition, interpretation, and
report; each additional lesion (List separately in addition to code for
primary procedure)
96999

Deleted Codes
0475T – Recording of fetal magnetic cardiac signal using at least 3
channels; patient recording and storage, data scanning with signal
extraction, technical analysis and result, as well as supervision, review,
and interpretation of report by a physician or other qualified health care
professional
93799
0476T - Recording of fetal magnetic cardiac signal using at least 3
channels; patient recording, data scanning, with raw electronic signal
transfer of data and storage
93799
channels; signal extraction, technical analysis, and result
93799
channels; review, interpretation, report by physician or other qualified
health care professional
93799

Deleted Codes
0487T – Biomechanical mapping, transvaginal, with report 58999
0493T - Contact near-infrared spectroscopy studies of lower extremity
wounds (eg, for oxyhemoglobin measurement)
93998
0497T - External patient-activated, physician- or other qualified health
care professional-prescribed, electrocardiographic rhythm derived event
recorder without 24-hour attended monitoring; in-office connection
93799
0498T - External patient-activated, physician- or other qualified health
care professional-prescribed, electrocardiographic rhythm derived event
recorder without 24-hour attended monitoring; review and interpretation
by a physician or other qualified health care professional per 30 days
with at least one patient-generated triggered event
93799

Deleted Codes
0514T – Intraoperative visual axis identification using patient fixation (List
separately in addition to code for primary procedure)
None
0702T - Remote therapeutic monitoring of a standardized online digital
cognitive behavioral therapy program ordered by a physician or other
qualified health care professional; supply and technical support, per 30
days
98978
0703T - Remote therapeutic monitoring of a standardized online digital
cognitive behavioral therapy program ordered by a physician or other
qualified health care professional; management services by physician or
other qualified health care professional, per calendar month
98978

Revised Codes – New & Emerging
Technology
CPT Code 2023 Long Description 2022 Long Description
0733T Remote real-time, motion capture–based
neurorehabilitative therapy ordered by a
physician or other qualified health care
professional; supply and technical support,
per 30 days
Remote body and limb kinematic measurement-
based therapy ordered by a physician or other
qualified health care professional; supply and
technical support, per 30 days
0734T Remote real-time, motion capture–based
neurorehabilitative therapy ordered by a
physician or other qualified health care
professional; treatment management
services by a physician or other qualified
health care professional, per calendar month
Remote body and limb kinematic measurement-
based therapy ordered by a physician or other
qualified health care professional; treatment
management services by a physician or other
qualified health care professional, per calendar
month

2023 CPT Code Updates (CDM Focused)

More Related Content

What's hot (20)

Similar to 2023 CPT Code Updates (CDM Focused) (20)

More from Health Catalyst (20)

Recently uploaded (20)

2023 CPT Code Updates (CDM Focused)

Editor's Notes